The use of nebulization for the administration of inhaled steroids plays an important role in asthma patients who are unable to use pressurized aerosol or dry-powder inhalers effectively Moreover; the type of nebulizer used may affect how much drug is delivered to the lungs. and symptoms, and the use of rescue salbutamol).The primary efficacy endpoint was the variation in the pulmonary expiratory flow (PEF) at treatment end over the baseline visit. For the intent-to-treat population, in the BDP group mean PEF values increased statistically significantly from 5.2 f I .3 I s-I to 5.7 * I .6 I s-1, while in the FP group the increase was from 5.2 k I .2 I s-l to 5.8 + I .8 I s-l. Mean PEF values as per cent of predicted also increased in a statistically significant way from 7 I % to 77. I % in the BDP group, and from 70. I % to 76.9% in the FP group.The two treatments were equally well to1erated.A total of 23 and 32 patients in the BDP and FP groups, respectively, reported adverse events during the treatment period, and these were generally mild. In conclusion, the results of this study demonstrate that BDP 2400 I-18 day' and FP 2000 pg day', both suspensions for nebulization administered via a jet nebulizer; are equally effective, with an acceptable safety and tolerability profile, when used in adult patients with moderate persistent asthma.
INTRODUCTION

RESULTS
Patient population
Of the 222 patients screened for the study, 205 were randomized: 103 to the BDP group, and IO2 to the FP group.Three patients (one in the BDP group and two in the FP group) were excluded from the efficacy analysis sample due to protocol violations at selection, and 20 patients (7 in the BDP group and I3 in the FP group) were excluded from the PP analysis due to various reasons.The 
Evaluation
of efficacy: Signs and symptoms and rescue medication
In the ITT population, significant improvements in asthma symptoms over baseline were noted for both treatment groups at the end of the study. The number of patients reporting symptoms scores defined as 'excellent' rose from I6 (15.7%) at baseline to 54 (52.9%) at treatment end in the BDP group, and from I2 (I 2%) to 46 (46%) in the FP group, with the difference between the two groups being non-significant.When examining the means of the symptoms scores sum, values increased statistically significantly from 4.7 at baseline to 6.3 at treatment end in the BDP group (P<O*OO I), and from 4.6 to 6.3 in the FP group (PcO=OOl), with no significant difference found between the two treatments.
The number of symptom-free patients during the day (symptom score 0) increased significantly for the two groups at study end vs before treatment: from I3 patients to 43 in the BDP group, and from IO to 35 in the FP group. No significant between-group difference was found. Similarly, notable increases were also reported for the two groups in the number of symptom-free patients during the night, rising from 22 to 5 I in the BDP group, and from 2 I to 48 in the FP group. Again, no significant difference was noted between the two treatment arms. In the BDP group, the use of salbutamol as rescue medication was reduced from an average of 2.8 puffs day' during the run-in period to 2.2 puffs day-1 during the first 4 weeks of treatment, and then again to 2-O puffs day-1 during the last 8 weeks. Similarly, patients treated with FP reduced their need for salbutamol from an average of 2.6 puffs day' during the run-in phase to 2.2 puffs day-' during the initial 4 weeks of treatment, and again to 2. I puffs day' during the final 8 weeks. No significant difference was found between the two treatment groups.
Evaluation of safety
Safety data showed that both treatments were well tolerated.
During the treatment period, 23 (22.5%) patients in the BDP group and 32 (32%) in the FP group reported one or more adverse events ( Table 2 ). The number of adverse events reported was 30 (39.5%) and 46 (60.5%) in the BDP and FP groups, respectively, and these were generally mild (NS between treatments for both variables). In total, six patients reported adverse drug reactions: two (2%) in the BDP group, and four (4%) in the FP group, with two (25%) and six (75%) adverse drug reactions seen in the respective groups (NS between treatments for both parameters).
Furthermore, only one patient (0.9%) in the BDP group discontinued treatment due to treatment-related adverse events. Moreover, no significant difference was found between the two treatments with regard to laboratory tests, and no clinically relevant changes in vital signs or physical examination were observed in either treatment group.
DISCUSSION
Inhaled corticosteroids are very effective in controlling symptoms in asthmatic patients of all ages and disease severity (IO) to pMDls, especially when it is necessary to administer high doses of drug (>500 pg), and to avoid problems related to poor hand-respiration coordination that are seen in some patients that use pMDls.
